UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $55.00 price target on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.44) EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.51 EPS and FY2026 earnings at $0.27 EPS.

A number of other brokerages also recently weighed in on URGN. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. The Goldman Sachs Group reduced their target price on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. Guggenheim restated a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. Scotiabank started coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price objective for the company. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, UroGen Pharma presently has an average rating of “Buy” and a consensus target price of $32.86.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $9.85 on Tuesday. The stock has a market capitalization of $454.15 million, a PE ratio of -3.13 and a beta of 0.66. UroGen Pharma has a 1-year low of $8.94 and a 1-year high of $20.70. The firm has a fifty day simple moving average of $10.66 and a 200 day simple moving average of $10.94. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, research analysts expect that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Hedge Funds Weigh In On UroGen Pharma

A number of large investors have recently made changes to their positions in URGN. CWM LLC boosted its stake in UroGen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock valued at $58,000 after purchasing an additional 5,140 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of UroGen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC bought a new stake in shares of UroGen Pharma in the fourth quarter valued at about $67,000. GAMMA Investing LLC grew its stake in shares of UroGen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in UroGen Pharma during the fourth quarter worth about $101,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.